Navigation Links
InterMune to Webcast 2011 Analyst Day Presentations

BRISBANE, Calif., May 19, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) will conduct a live webcast of its 2011 Analyst Day presentations on Thursday, May 26, 2011, from 8:30 a.m. – 11:30 a.m. EDT in New York.  Presentations by InterMune's executive management team will provide an overview of the company's vision, strategy and a comprehensive update of InterMune's commercial and scientific plans.  The company also will provide details on its preparations to launch Esbriet® (pirfenidone) for the treatment of adult patients with mild to moderate idiopathic pulmonary fibrosis (IPF) in Europe and on ASCEND, a new Phase 3 study of pirfenidone, including study design, scientific rationale and guidance on important study and NDA resubmission milestones.

To access the webcast of the Analyst Day presentations, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at  The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes Esbriet® (pirfenidone), which is now approved in the European Union for the treatment of adults with mild to moderate IPF, a progressive and fatal lung disease.  The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs.  For additional information about InterMune and its R&D pipeline, please visit

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
2. InterMune to Present at Bank of America Merrill Lynch Health Care Conference
3. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 28
5. InterMune to Release Fourth Quarter and Full Year Financial Results on February 16
6. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
7. InterMune to Release Third Quarter Financial Results on October 28
8. InterMune Sells Danoprevir Rights to Roche for $175 Million
9. InterMune to Present at 2010 Citi Health Care Conference
10. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
11. InterMune to Release First Quarter Financial Results on April 29
Post Your Comments:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
Breaking Biology Technology:
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):